





## Challenges for Calves

# Reasons for Mortality



# Challenges for Calves



## Potential Tools

### Vaccines

- Slow immune response
- Low effect against GI tract infections

### Antibiotics

- Resistance
- Drug residues in food
- Not effective against viral infections
- Also harms good microbial flora in intestine

### Blood plasma, colostrum, etc.

- Non specific antibodies
- Safety problems



Chicken egg immunoglobulins (IgY)

# Facts about Colostrum

- Calves are dependent on receiving maternal antibodies via colostrum
- Colostrum varies greatly in type and concentration of antibodies
- Animals receiving inadequate colostrum are extremely vulnerable to intestinal infection and subsequent scours

# Environmental Challenges

- Hygienic conditions
  - in the calving stable
  - of the water
  - of the milk / feed
- Housing conditions
  - no fresh air
  - wrong temperature
- Management
  - during birt



# Nutritional Challenges

- Insufficient colostrum and milk replacer (quality /quantity)
  - High yielding cows produce colostrum of less quality (limits of the genetic potential)
  - Inadequate temperature
- Wrong timing of first colostrum feeding
- An energy deficit causes a loss of body temperature
- Energy is also needed to build up the body's own immune system

# Immunological Challenges

- Calves are born without any immune protection and own immune system develops slowly
- Essential supply of immunoglobulins by the colostrum
- The immunoglobulin level in the cow's colostrum rapidly decreases
- Absorption of immunoglobulins into blood mainly within 6 – 24 hours after birth

# Role of Colostrum

## Comparison between colostrum and normal milk

	Within 3 days of birth	After 3 days of birth
Immunoglobulin G (IgG)	50mg/mL	0.6mg/mL
Immunoglobulin A (IgA)	4mg/mL	0.15mg/mL
Immunoglobulin M (IgM)	4mg/mL	0.05mg/mL
Vitamin A	200~ 300 $\mu$ g/dL	33 $\mu$ g/dL
Solids	18~24%	13%
Fat	5~7%	4%
Protein	8~14%	3%

# Immunological Status

## Time of colostrum intake and total Ig absorption

Hrs after birth	Calf serum Ig [mg/ml]	% Absorption
6	52.7	66
12	37.5	47
24	9.2	12
36	5.4	7
48	4.8	6




Reference: *Vet. Rec.* 114:157

# Immunity gap in young animals




# Disease pressure in neonatal calves

Main causal agents of diarrhea are pathogens:



# Pathological Challenges of Calves



# **Specific IgY powder Trials**

## In vivo study – Ig 0032


**Protection of neonatal calves against fatal enteric colibacillosis by administration of specific IgY powder from hens immunized with K99-piliated enterotoxigenic *E.coli***

*Ikemori et al., 1992, Am J Vet Res 53: 2005-2008*

## In vivo study – Material and Methods

Animals	16 neonatal calves, 4 groups
Antibody	K99 fimbrial of Enterotoxigenic <i>Escherichia coli</i> (ETEC)
Groups	Control <b>IgY (3 different titers)</b>
Challenge	K99+ ETEC: $1.6 \times 10^{11}$ CFU / calf
Test period	2 to 8 days of age
Observations	<ol style="list-style-type: none"><li>1. Clinical symptoms</li><li>2. Body weight</li></ol>

# In vivo study: Results - Mortality



Results with different letters differ statistically ( $P < 0,01$ )

**In vivo study – Ig 0029**


**Prevention of fatal salmonellosis in neonatal  
calves, using orally administered IgY  
*Salmonella*-specific antibodies**

*Yokoyama et al., 1998, Am J Vet Res 59*

# In vivo study – Material and Methods

Animals	38 Neonatal Holstein calves from <i>Salmonella</i> free farms
Antibody	<i>Salmonella typhimurium</i> (ST) or <i>Salmonella dublin</i> (SD)
Groups	Control <b>anti ST-IgY (3 different titers)</b> <b>anti SD-IgY (2 different titers)</b>
Challenge	<i>S. typhimurium</i> 10 <sup>11</sup> CFU / calf <i>S. dublin</i> 10 <sup>11</sup> CFU / calf
Test period	1 to 14 days of age
Observations	<ol style="list-style-type: none"><li>1. Clinical symptoms</li><li>2. Body weight</li></ol>

## In vivo study – Results (*Salmonella typhimurium*)



\* P<0,05; \*\* P<0,01

**In vivo study – Ig 0030**





**Passive protection against bovine  
rotavirus in calves by specific IgY**

*Kuroki et al., 1994, Arch Virol 138: 143-148*

## In vivo study – Material and Methods

Animals	24 neonatal calves
Antibody	against Bovine Rotavirus (BRV) serotypes G 6 or G 10
Groups	Control <b>Specific IgY (3 different titers)</b>
Challenge	BRV serotypes G6 $1 \times 10^{10}$ TCID <sub>50</sub> / calf BRV serotypes G10 $5 \times 10^9$ TCID <sub>50</sub> / calf
Test period	2 to 10 days of age
Observations	<ol style="list-style-type: none"><li>1. Clinical symptoms</li><li>2. Body weight</li></ol>

# In vivo study – Results diarrhea incidence



## **In vivo study**


### **Passive protection of neonatal calves against Bovine Coronavirus (BCV) –induced diarrhoea by administration of specific IgY or colostrum antibody**

*Ikemori et al., 1997, Veterinary Microbiology 58: 105-111*


# In vivo study: Materials and Methods

Animals	23 neonatal calves
Antibody	against Bovine Coronavirus (BCV)
Groups	Control Specific IgY: Group x1 titer, Group x2 titer Colostrum IgG: Group x2 titer, Group x4 titer, Group x8 titer
Challenge	BCV: $1 \times 10^9$ TCID <sub>50</sub> / calf
Test period	2 to 8 days of age
Observations	<ol style="list-style-type: none"><li>1. Clinical symptoms</li><li>2. Fecal score</li><li>3. Body weight</li></ol>


# In vivo study: Results – Mortality rate



# In vivo study: Results – Diarrhea incidence



## In vivo study: Results – Cumulative fecal score



**Specific IgY powder  
Field Trials**

# Field trial – Specific IgY powder

## Effect of Specific IgY powder added to milk replacer on calf growth performance

*Institute trial at LVA Futterkamp, Germany, 1997*


## Field trial – Material and Methods

Animals	50 male Holstein Friesian calves Housed at 14 days of life
Groups	Control: 25 animals Specific IgY powder: 25 animals
Dosage	Day 1 – 14: 5 g/animal/day (mixed into the calf milk) Day 15 – end: no administration of Globigen®
Challenge	Field trial
Trial duration	07 <sup>th</sup> of April until 21 <sup>st</sup> of October
Observations	Body weight (every 4 weeks)

## Field trial – Results

Date	Average weight per animal (kg)	
	Control	Specific IgY powder
07.04. (Start weight)	54	55
30.04.	55	57
27.05.	71	77
01.07.	99	109
29.07.	135	147
26.08.	170	181
23.09.	217	227
21.10. (End weight)	252	262

# Field trial – Results



**Start**

**Effects of Specific IgY powder on performance  
and meat parameters of veal calves**

Field trial Holdorf region, Germany, 2010


## Field Trial: Specific IgY powder

Groups	Control: 360 calves (120 before, 238 after trial group) Specific IgY powder: 94 calves Comparison group (data from “Westfleisch”): 39,000 calves
Genetics	HF
Challenge	Field trial
Feeding system	Computer assisted
Trial duration	<b>From day 1 to week 26</b>
Observations	Growth performance Slaughter performance Medicine costs


## Field trial: Specific IgY powder

<b>Application time</b>	<b>Specific IgY powder (g/animal &amp; day)</b>
day 1	20 g
day 2	15 g
day 3	10 g
day 4 to 14	6 g
week 3 to 26	1 g

## Field trial: Specific IgY powder - RESULTS



## Field trial: Specific IgY powder - RESULTS



## Field trial: Specific IgY powder - RESULTS

Parameter	Comparison Westfleisch 2009 (39,000 calves)	Control group	Specific IgY
Final body weight (kg)		276,72	<b>286,52</b>
Slaughter weight (kg)	141,94	144,65	<b>149,75</b>
Daily gain (g)	Not specified	1241	<b>1378</b>
Daily gain ref. to slaughter weight (g)	690	649	<b>720</b>
FCR*	Not specified	1,57	<b>1,49</b>
Fattening period (days)	Not specified	223	<b>208</b>

\*FCR only related to milk replacer consumption without inclusion of other feed (hay, corn, etc.)



Conclusion Specific IgY powder Trials

**Over 80 trials in more than 10 years**

**Field trials, trial facilities, universities**

**95% positive outcome → zootechnical parameters improved**

# Specific IgY

## Several (field) trials show:

- Improved general health status
- Less diarrhea
- Better daily gain
- Less medication costs
- Reduction in mortality

